The European Medicines Agency (EMA) has recommended that the multiple sclerosis drug Gilenya® (fingolimod) should not be used in pregnant women and women of childbearing potential who do not use effective contraception.

To the risk information full text (available in German only)

More information about Gilenya can be found on the EMA website: